Xoma Royalty Corp XOMAP 价格预测与展望

Q: 技术分析指标如何适用于 XOMAP？

根据技术分析，Xoma Royalty Corp 的综合信号为 Sell。Xoma Royalty Corp 有 2 个买入信号，2 个中性信号和 3 个卖出信号。

Q: XOMAP 的斐波那契回调水平是多少？

Xoma Royalty Corp 的斐波那契回调水平是 在 23.6% 和 38.2% 之间。

Q: Xoma Royalty Corp 的 RSI 是多少？

Xoma Royalty Corp 的 RSI 目前为 49.37，表明处于 中立 状态

Q: Xoma Royalty Corp 接下来 12 个月的价格是多少？

Xoma Royalty Corp XOMAP 接下来 12 个月的价格预计为 $64.44。

Q: Xoma Royalty Corp 预计会涨到多高？

据华尔街分析师称，Xoma Royalty Corp 预计将达到 $99.76 的高预测值。

主页

股票

XOMAP

预测

XOMAP 股票价格预测

Xoma Royalty Corp

$26.29

-0.72%

$-0.19

收盘价：Jan 26, 16:00:00 GMT-5

$26.29

盘后：Jan 26, 17:38:51 GMT-5

概述预测收益股息财务数据

关键数据

前收盘价

$26.48

开盘价

$26.34

当日区间

$26.29 - $26.34

52周范围

$24.96 - $30

交易量

1.6K

平均成交量

1.1K

每股收益（TTM）

1.91

股息收益率

1.75%

市值

$325.4M

什么是 XOMAP？

XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 13 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.

功能特性

交易策略

资源

市场

Utilizing our sophisticated predictive model, we anticipate notable price fluctuations for XOMAP in the upcoming periods. Looking toward the future, our 2027 projection indicates an average price target of $64.44. The lowest target is $44.51 and the highest is $99.76. Empower your investment choices with our cutting-edge, data-driven analysis!

XOMAP 股价预测摘要

XOMAP的顶级分析师评级

基于 10 位分析师对 XOMAP 的股票评级，更新于 Dec 01, 2025

Buy

Strong buy

Buy

Hold

Sell

Strong sell

Leveraging in-depth analyst evaluations, we have synthesized key insights from expert assessments to present a positive outlook for XOMAP. Analysts highlight solid fundamentals and favorable market sentiment, suggesting upside potential in the near term. Based on this thorough expert analysis, we maintain an optimistic view of this stock. Our conclusion: XOMAP is a Buy candidate.

XOMAP stock price ended at $26.48 on 星期五, after rising 0.57%

On the latest trading day Jan 23, 2026, the stock price of XOMAP rose by 0.57%, climbing from $26.30 to $26.48. During the session, the stock saw a volatility of 0.72%, with prices oscillating between a daily low of $26.29 and a high of $26.48. Notably, trading volume dropped by 257 shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 2.0K shares were traded, equating to a market value of approximately $327.8M.

XOMAP 技术面信号

技术面信号摘要

购买信号 2

中性信号 2

卖出信号 3

Strong Sell

Sell

Neutral

Buy

Strong Buy

XOMAP目前显示2个买入信号和3个卖出信号。该股票自12:00 AM以来一直处于上升趋势状态，在此期间价格总变动为1.38%。总体而言，技术指标显示中期前景为Sell。

XOMAP 的看涨/看跌信号

我们的算法通过分析移动平均线、RSI、MACD 和成交量等关键指标，为 XOMAP 生成看涨和看跌信号。这些见解可助您做出明智的投资决策。

后续问题

技术分析指标如何适用于 XOMAP？



XOMAP 的斐波那契回调水平是多少？



Xoma Royalty Corp 的 RSI 是多少？



Xoma Royalty Corp 接下来 12 个月的价格是多少？



Xoma Royalty Corp 预计会涨到多高？



Xoma Royalty Corp（XOMAP）价格

XOMAP 股价走势图